Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06272071

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection

The goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with severe hepatitis (liver failure). The main questions it aims to answer are:

* Mapping of infectious agents in patients with severe hepatitis (liver failure) * Constructing early warning predictive models to explore how to give an individualized regimen of integrated immune function.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Liver Failure Digestive System Diseases Hepatic Insufficiency Hepatitis Liver Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

About this study

Liver failure is a clinical syndrome caused by a large number of necrotic hepatocytes leading to severe liver function damage, with jaundice, coagulation dysfunction and hepatic encephalopathy as the main manifestations, which can be caused by a variety of reasons, and the liver failure caused by Hepatitis B Virus (HBV) is the first one in our country, which accounts for about 80% of the cases. Through the "Eleventh Five-Year Plan" to "Thirteenth Five-Year Plan" national scientific and technological major special projects, the death rate of patients with early and middle stage of severe hepatitis B has been significantly reduced, but the death rate of patients with advanced stage is still as high as about 60%, especially when liver failure is combined with other complications, such as This study focuses on the impact of secondary infections on the clinical prognosis of severe hepatitis (liver failure), and intends to establish a prospective, multi-center clinical cohort of secondary infections in liver failure, map the infectious pathogens, correlate the basic immune status with the characteristics of the pathogen profile of the secondary infections, and establish a monitoring and early-warning system of secondary infections, so as to explore safe and effective treatment modalities. To further reduce the mortality rate of liver failure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients agreed to participate in the study and signed an informed consent form;
  • Sex is not limited and age is 18-70 years old;
  • HBsAg positive for more than 6 months, or hepatitis E IgM positive, or hepatitis E RNA positive;
  • Progressive deepening of jaundice in a short period of time (serum total bilirubin greater than 10 times the upper limit of normal or rising ≥17.1 umol/L per day);
  • Sgnificant bleeding tendency with PTA ≤ 40% and exclusion of other non-hepatic factors.

Exclusion criteria

  • Patients with severe hepatitis caused by other non-hepatophilic viral infections;
  • Patients who were considered by the investigator to be unsuitable for participation in the study.

Treatment and study plan

Primary outcomes

  1. Occurrence of secondary infections in patients with severe viral hepatitis (liver failure) at 4 weeks, including site of infection and pathogen of infection.

    Time frame: 4 weeks

    Site of infection, pathogen results such as blood or body fluid pathogen cultures or Next-generation sequencing(NGS) results.

  2. quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks

    Time frame: 4 weeks

    qSOFA consists of 3 items: altered state of consciousness, systolic blood pressure ≤ 100 mmHg, and respiratory rate ≥ 22 respirations/min. 2 or more items, i.e., a qSOFA score of ≥ 2, are considered to be suspicious for sepsis.Higher qSOFA scores are associated with a higher risk of patient death.

Secondary outcomes

  1. Occurrence of secondary infections in patients with severe viral hepatitis (liver failure) at 8 weeks, including site of infection and pathogen of infection.

    Time frame: 8 weeks

    Site of infection, pathogen results such as blood or body fluid pathogen cultures or NGS results.

  2. Occurrence of secondary infections in patients with severe viral hepatitis (liver failure) at 12 weeks, including site of infection and pathogen of infection.

    Time frame: 12 weeks

    Site of infection, pathogen results such as blood or body fluid pathogen cultures or NGS results.

  3. qSOFA score at 8 weeks

    Time frame: 8 weeks

    qSOFA consists of 3 items: altered state of consciousness, systolic blood pressure ≤ 100 mmHg, and respiratory rate ≥ 22 respirations/min. 2 or more items, i.e., a qSOFA score of ≥ 2, are considered to be suspicious for sepsis.Higher qSOFA scores are associated with a higher risk of patient death.

  4. qSOFA score at 12 weeks

    Time frame: 12 weeks

    qSOFA consists of 3 items: altered state of consciousness, systolic blood pressure ≤ 100 mmHg, and respiratory rate ≥ 22 respirations/min. 2 or more items, i.e., a qSOFA score of ≥ 2, are considered to be suspicious for sepsis.Higher qSOFA scores are associated with a higher risk of patient death.

Study contacts

Contact information is provided by the study sponsor or research team.

Jiajia Chen

CONTACT

[email protected]

+8615967109232

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Collaborators

  • Beijing Ditan Hospital
  • Beijing YouAn Hospital
  • Huashan Hospital
  • Qilu Hospital of Shandong University

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Feb 22, 2024
Registry last updated
Mar 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.